Comprehensive, personalized alpha-1 support for patients and physicians and their practices

When you prescribe PROLASTIN®-C (alpha1-proteinase inhibitor [human]), you and your patients gain immediate access to all the benefits of the PROLASTIN DIRECT program. Call 1-800-305-7881 to speak with a Patient Service Coordinator.


Devoted Alpha-1 Care Team1

  • Dedicated patient service coordinators assist patients every step of the way:
    • Help coordinate support services for your patients taking PROLASTIN-C
    • Manage the program's streamlined enrollment process
    • Relieve the administrative burden of starting your patients on therapy

  • Just 1 number connects you and your patients to a devoted Alpha-1 Care Team
    • Call 1-800-305-7881 to speak with a Patient Service Coordinator

See how the PROLASTIN DIRECT program simplifies the process— from enrollment to therapy to ongoing support.

Insurance and Reimbursement Specialists1

  • PROLASTIN-C is covered by most major insurance providers
  • Your PROLASTIN DIRECT Alpha-1 Care Team includes dedicated insurance and reimbursement specialists who:
    • Manage the preauthorization and verification process for treatment and benefits
    • Assist with any complexities that may arise
  • A patient assistance program is available for eligible patients

See how the PROLASTIN DIRECT program insurance and reimbursement specialists can help secure coverage.

Specialty Pharmacy and Infusion Experts1

  • Your PROLASTIN DIRECT Alpha-1 Care Team's Specialty Pharmacy and Infusion Experts:
    • Offer 24/7 on-call support with a registered nurse and pharmacists
    • Provide access to a dedicated pharmacy that coordinates shipments, scheduling, and supply needs
    • Coordinate infusion therapy at a time that's convenient to your patient— at home, at a clinic, or when traveling — at no additional cost to the patient when insurance allows
  • Patients enrolled in the PROLASTIN DIRECT program have a compliance rate of 98.4%

Learn more about the support and infusion coordination provided by the PROLASTIN DIRECT program.

Fully Integrated Disease Management1,2

  • The PROLASTIN DIRECT program connects patients to the AlphaNet® Alpha-1 Disease Management and Prevention Program (ADMAPP)
  • In an ADMAPP Health Outcomes Study, patients experienced a significant2:
    • Reduction in exacerbations (10%)
    • Increase in long-acting bronchodilator use (15%)
      • Translates into more optimal medication use
    • Reduction in unscheduled physician visits (12%)
    • Reduction in emergency room visits (21%)
  • Patients receive monthly calls by certified AlphaNet coordinators who provide peer support and personalized education

Learn about how ADMAPP from the PROLASTIN DIRECT program may help your patients.

Partners

Grifols

Grifols, the manufacturer of PROLASTIN-C, is a global healthcare company, founded in 1940, whose mission is to improve the health and well-being of people around the world.

The PROLASTIN DIRECT program and Dohmen Life Science Services

Dohmen Life Science Services manages the PROLASTIN DIRECT program. A patient-centered service organization composed of pharmacy, insurance, and home healthcare experts, this fully dedicated specialty alpha-1 pharmacy provides your practice and your patients with administrative, clinical, and financial support.

PROLASTIN-C is available only through the PROLASTIN DIRECT program.

AlphaNet

AlphaNet is a not-for-profit organization of Alphas Serving Alphas®. A team of expert AlphaNet coordinators, all alphas themselves, are devoted to helping improve the lives of alphas receiving treatment with PROLASTIN-C.

 


PROLASTIN-C is available only through the PROLASTIN DIRECT program.


PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI), including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.

PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C is contraindicated in IgA-deficient patients with antibodies against IgA due to the risk of severe hypersensitivity and in patients with a history of anaphylaxis or other severe systemic reactions to alpha1-PI.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. Should hypersensitivity symptoms be observed, promptly stop infusion and begin appropriate therapy. Have epinephrine and other appropriate therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

The most common drug-related adverse reaction observed at a rate of >5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

Please click here for full Prescribing Information for PROLASTIN-C.


References

  1. Data on file, PROLASTIN DIRECT program.
  2. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.